Related Experiment Video
Updated: Jun 2, 2026
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
EMMPRIN levels in serum of patients with amyotrophic lateral sclerosis
1Department of Neurological Rehabilitation, Medical University in Lublin, Poland. ilzecka@onet.pl
Objectives:
There are evidence that extracellular matrix metalloproteinases (MMPs) may be implicated in the pathophysiology of amyotrophic lateral sclerosis (ALS). The extracellular matrix metalloproteinase inducer (EMMPRIN) is said to increase the production of MMPs in cells. The aim of the study was to investigate serum EMMPRIN levels in patients with ALS.
Materials And Methods:
The study included 50 patients with ALS and 50 patients from the control group. Serum EMMPRIN levels were measured using the enzyme-linked immunosorbent method.
Results:
The study showed that EMMPRIN levels are significantly increased in the serum of the whole group of patients with ALS when compared to the control group and are significantly increased in patients with ALS with severe clinical state compared to patients with mild clinical state (P < 0.05). There was a significant correlation of serum EMMPRIN levels with severity of clinical state of patients with ALS (P < 0.05).
Conclusion:
The results indicate that EMMPRIN is implicated in pathophysiology of ALS and may be the marker of clinical state severity.
Insights
Extracellular matrix metalloproteinase inducer (EMMPRIN) levels are elevated in amyotrophic lateral sclerosis (ALS) patients. Higher EMMPRIN serum levels correlate with ALS clinical severity, suggesting its role in disease progression.
Area of Science:
- Neuroscience
- Biochemistry
- Pathophysiology
Background:
- Extracellular matrix metalloproteinases (MMPs) are implicated in amyotrophic lateral sclerosis (ALS) pathogenesis.
- Extracellular matrix metalloproteinase inducer (EMMPRIN) stimulates MMP production.
Purpose of the Study:
- To investigate serum EMMPRIN levels in ALS patients.
- To determine the association between EMMPRIN levels and ALS clinical severity.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure serum EMMPRIN.
- Study included 50 ALS patients and 50 controls.
Main Results:
- Serum EMMPRIN levels were significantly higher in ALS patients compared to controls.
- Elevated EMMPRIN levels were observed in severe ALS cases versus mild cases.
- A significant correlation was found between serum EMMPRIN levels and ALS clinical severity.
Conclusions:
- EMMPRIN is implicated in the pathophysiology of ALS.
- Serum EMMPRIN may serve as a biomarker for ALS clinical severity.
More Related Videos
08:16Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Related Concept Videos
01:37Neural Regulation
01:11Alterations in Muscle Tone lll